Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies the effect of pembrolizumab and lenvatinib in treating
patients with high-grade serous ovarian cancers. Immunotherapy with monoclonal antibodies
such as pembrolizumab may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. Lenvatinib is an enzyme inhibitor that
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving pembrolizumab and lenvatinib may help to control the disease and provide an effective
therapeutic option for cancer.